ESLA.O (ESLA.O) News
Follow ESLA.O (ESLA.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth STARLIGHT — 1 Trial Site
Oct 14 (Reuters) — Estrella Immunopharma Inc: Estrella Immunopharma Activates Intermountain Health Lds Hospital As Fifth Clinical Site For Phase I/ii Starlight-1 Trial In B-cell Non-hodgkin’s Lymphoma Source text:... Fur
NEWS | Oct 14, 2026, 09:38 PM UTC
L
Estrella Immunopharma Adds Fifth Site for Phase I/II EB103 Trial in B — Cell Non — Hodgkin’s Lymphoma
Estrella Immunopharma activated Intermountain Health LDS Hospital as the fifth site for its Phase I/II STARLIGHT-1 trial of EB103. The Salt Lake City hospital is expected to begin screening and enrolling patients with re
NEWS | Oct 14, 2026, 08:20 PM UTC
H
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT — 1 Trial in B — cell Non — Hodgkin’s Lymphoma
For best results when printing this announcement, please click on link below: Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgki
CENTRAL_BANK | Oct 14, 2026, 08:17 PM UTC